Rothschild & CO Asset Management Us Inc. Ionis Pharmaceuticals Inc Transaction History

Rothschild & CO Asset Management Us Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 08, 2021	SELL	$45.3 - $60.27 $10.1 Million - $13.4 Million	-222,045 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$47.45 - $62.95 $2.26 Million - $3 Million	-47,615 Reduced 17.66%	222,045 $10.5 Million
Q2 2020 Aug 10, 2020	SELL	$46.85 - $61.05 $3.48 Million - $4.54 Million	-74,367 Reduced 21.62%	269,660 $15.9 Million
Q1 2020 May 14, 2020	SELL	$41.6 - $63.4 $1.26 Million - $1.92 Million	-30,341 Reduced 8.1%	344,027 $16.3 Million
Q4 2019 Feb 12, 2020	BUY	$53.85 - $65.27 $6.86 Million - $8.31 Million	127,346 Added 51.55%	374,368 $22.6 Million
Q3 2019 Nov 08, 2019	SELL	$59.06 - $72.15 $325,952 - $398,195	-5,519 Reduced 2.19%	247,022 $14.8 Million
Q2 2019 Jul 25, 2019	SELL	$62.09 - $86.14 $2.16 Million - $2.99 Million	-34,735 Reduced 12.09%	252,541 $16.2 Million
Q1 2019 May 08, 2019	BUY	$52.92 - $81.17 $697,697 - $1.07 Million	13,184 Added 4.81%	287,276 $23.3 Million
Q4 2018 Feb 05, 2019	SELL	$43.37 - $59.54 $79,323 - $108,898	-1,829 Reduced 0.66%	274,092 $14.8 Million
Q3 2018 Nov 13, 2018	SELL	$42.88 - $53.7 $303,547 - $380,142	-7,079 Reduced 2.5%	275,921 $14.2 Million
Q2 2018 Aug 07, 2018	BUY	$40.53 - $50.7 $99,257 - $124,164	2,449 Added 0.87%	283,000 $11.8 Million
Q1 2018 May 08, 2018	SELL	$44.08 - $55.05 $115,754 - $144,561	-2,626 Reduced 0.93%	280,551 $12.4 Million
Q4 2017 Feb 12, 2018	BUY	$50.3 - $64.39 $106,082 - $135,798	2,109 Added 0.75%	283,177 $14.2 Million
Q3 2017 Nov 08, 2017	BUY	$45.56 - $59.57 $12.8 Million - $16.7 Million	281,068	281,068 $14.3 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.